PL1648502T3 - Szczepionki przeciwko HCV - Google Patents

Szczepionki przeciwko HCV

Info

Publication number
PL1648502T3
PL1648502T3 PL04763141T PL04763141T PL1648502T3 PL 1648502 T3 PL1648502 T3 PL 1648502T3 PL 04763141 T PL04763141 T PL 04763141T PL 04763141 T PL04763141 T PL 04763141T PL 1648502 T3 PL1648502 T3 PL 1648502T3
Authority
PL
Poland
Prior art keywords
epitope
hcv
hcv vaccines
hotspot
vlcecydag
Prior art date
Application number
PL04763141T
Other languages
English (en)
Inventor
Michael Buschle
Jürgen Frisch
Christoph Klade
Karen Lingnau
Wolfgang Zauner
Gerd Zettlmeissl
Original Assignee
Intercell Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Ag filed Critical Intercell Ag
Publication of PL1648502T3 publication Critical patent/PL1648502T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PL04763141T 2003-07-11 2004-07-09 Szczepionki przeciwko HCV PL1648502T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP03450171 2003-07-11
EP04450062 2004-03-12
EP04763141A EP1648502B1 (en) 2003-07-11 2004-07-09 Hcv vaccines
PCT/EP2004/007540 WO2005004910A2 (en) 2003-07-11 2004-07-09 Hcv vaccines

Publications (1)

Publication Number Publication Date
PL1648502T3 true PL1648502T3 (pl) 2011-05-31

Family

ID=34066530

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04763141T PL1648502T3 (pl) 2003-07-11 2004-07-09 Szczepionki przeciwko HCV

Country Status (11)

Country Link
US (3) US20070031446A1 (pl)
EP (2) EP1648502B1 (pl)
JP (2) JP4734241B2 (pl)
CN (1) CN1822856B (pl)
AT (1) ATE489967T1 (pl)
AU (1) AU2004255456B2 (pl)
CA (1) CA2530062A1 (pl)
DE (1) DE602004030343D1 (pl)
PL (1) PL1648502T3 (pl)
TW (1) TWI358301B (pl)
WO (1) WO2005004910A2 (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711670B1 (fr) 1993-10-22 1996-01-12 Pasteur Institut Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US7776343B1 (en) 1999-02-17 2010-08-17 Csl Limited Immunogenic complexes and methods relating thereto
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US7807803B2 (en) 2002-07-03 2010-10-05 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) 2002-07-03 2004-03-18 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EA008777B1 (ru) 2002-10-29 2007-08-31 Коли Фармасьютикал Груп, Лтд. Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
CA2502015A1 (en) 2002-12-11 2004-06-24 Coley Pharmaceutical Group, Inc. 5' cpg nucleic acids and methods of use
CN1822856B (zh) * 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
WO2005094891A2 (en) * 2004-03-12 2005-10-13 Intercell Ag Method for solubilising peptide mixtures
EP1804822B1 (en) * 2004-10-29 2009-07-22 Intercell AG Hcv vaccines for chronic hcv patients
EP1863531A1 (en) * 2005-03-19 2007-12-12 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
CN101426514A (zh) * 2006-04-25 2009-05-06 英特塞尔股份公司 Hcv疫苗
NZ575437A (en) 2006-09-27 2012-02-24 Coley Pharm Gmbh Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
WO2010039195A2 (en) * 2008-09-23 2010-04-08 The Board Of Trustees Of The Leland Stanford Junior University Screening for inhibitors of hcv amphipathic helix (ah) function
WO2010054446A1 (en) * 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
US20120046188A1 (en) * 2009-03-30 2012-02-23 bioMerieux, SA Solid Support for HCV Detection
US20100322943A1 (en) 2009-06-17 2010-12-23 Thomas Cantor Therapeutic and diagnostic affinity purified specific polyclonal antibodies
EP2484378A4 (en) 2009-09-30 2013-05-22 Toray Industries VACCINE COMPOSITION AGAINST HEPATITIS C VIRUS
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
US9752494B2 (en) 2013-03-15 2017-09-05 Kohler Co. Noise suppression systems
US11596679B2 (en) * 2017-04-27 2023-03-07 Vanderbilt University Hepatitis C virus gene sequences and methods of use therefor
CN109212220B (zh) * 2018-09-21 2021-06-29 北京凯因科技股份有限公司 丙型肝炎病毒抗体快速检测试纸条

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683864A (en) * 1987-11-18 1997-11-04 Chiron Corporation Combinations of hepatitis C virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
DE3834729A1 (de) * 1988-10-12 1990-04-19 Behringwerke Ag Verwendung von zink-oder eisenhydroxid zur adjuvierung von antigenloesungen und auf diese weise adjuvierte antigenloesungen
US5562910A (en) * 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
ATE346302T1 (de) 1990-08-25 2006-12-15 Bioprocess Pty Ltd Nicht-a, nicht-b hepatitis virus antigen, und diagnostische verfahren.
RO117329B1 (ro) * 1991-06-24 2002-01-30 Chiron Corp Emeryville Polipeptide care contin o secventa a virusului hepatitei c
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US20030152580A1 (en) * 1994-07-21 2003-08-14 Alessandro Sette Hla binding peptides and their uses
US5333965A (en) 1992-01-31 1994-08-02 Mailey John W In situ modular fastening system
KR960700739A (ko) 1993-03-05 1996-02-24 카린 이스텀 Hla-a2. 1 결합 펩티드 및 그의 용도(hla-a2. 1 binding peptides and their uses)
BR9405334A (pt) 1993-04-27 1999-05-25 Innogenetics Nv Novas sequências de genótipos de vírus da hepatite c e seu uso como agentes terapêuticos e diagnóstico
US5709995A (en) 1994-03-17 1998-01-20 The Scripps Research Institute Hepatitis C virus-derived peptides capable of inducing cytotoxic T lymphocyte responses
AU697171B2 (en) 1994-04-08 1998-10-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Hepatitis C virus core peptide for stimulation of cytotoxic T lymphocytes and diagnosis of HCV exposure
AUPM543894A0 (en) * 1994-05-04 1994-05-26 Commonwealth Scientific And Industrial Research Organisation An adjuvant
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US6231859B1 (en) * 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
EP0855184A1 (en) * 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
CA2289040A1 (en) * 1997-05-01 1998-11-05 Protechtion Unlimited, Inc. Nerve growth factor as a vaccine adjuvant
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
ATE357526T1 (de) 1998-08-21 2007-04-15 Us Gov Health & Human Serv Modifizierte hcv peptid-impfstoffe
WO2001021189A1 (en) * 1999-07-19 2001-03-29 Epimmune Inc. Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20090130135A1 (en) * 1999-10-01 2009-05-21 Michael Buschle Hcv vaccines
AT409085B (de) * 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
ATE375169T1 (de) 2000-04-14 2007-10-15 Intercell Ag Modifizierte peptide enthaltende pharmazeutische präparationen
DE60100814T2 (de) * 2000-06-08 2004-07-01 Intercell Biomedizinische Forschungs- Und Entwicklungs Gmbh Immunstimulierende oligodeoxynukleotide
JP2004506019A (ja) 2000-08-17 2004-02-26 インターツェル・アクチェンゲゼルシャフト 少なくとも１つの抗原およびカテリシジン由来の抗菌ペプチドまたはその誘導体を含むワクチン
AT410635B (de) * 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
US6588670B2 (en) * 2001-10-30 2003-07-08 Symbol Technologies, Inc. Medical diagnostic monitoring
WO2003047602A1 (en) * 2001-12-07 2003-06-12 Intercell Ag Immunostimulatory oligodeoxynucleotides
FR2843115B1 (fr) * 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
AU2003258672B2 (en) 2002-09-13 2008-10-30 Intercell Ag Method for isolating hepatitis C virus peptides
AU2004224746B2 (en) * 2003-03-24 2009-04-23 Valneva Austria Gmbh Improved vaccines
CN1822856B (zh) * 2003-07-11 2010-04-28 英特塞尔股份公司 Hcv疫苗
EP1804822B1 (en) * 2004-10-29 2009-07-22 Intercell AG Hcv vaccines for chronic hcv patients

Also Published As

Publication number Publication date
AU2004255456B2 (en) 2010-06-24
WO2005004910A3 (en) 2005-04-21
EP2275131A2 (en) 2011-01-19
EP2275131A3 (en) 2012-01-25
TW200503752A (en) 2005-02-01
JP4734241B2 (ja) 2011-07-27
JP2011088916A (ja) 2011-05-06
JP2009513542A (ja) 2009-04-02
CA2530062A1 (en) 2005-01-20
AU2004255456A1 (en) 2005-01-20
DE602004030343D1 (de) 2011-01-13
US20110300170A1 (en) 2011-12-08
WO2005004910A2 (en) 2005-01-20
ATE489967T1 (de) 2010-12-15
CN1822856B (zh) 2010-04-28
CN1822856A (zh) 2006-08-23
US20090155294A1 (en) 2009-06-18
EP1648502B1 (en) 2010-12-01
TWI358301B (en) 2012-02-21
US20070031446A1 (en) 2007-02-08
EP1648502A2 (en) 2006-04-26

Similar Documents

Publication Publication Date Title
PL1648502T3 (pl) Szczepionki przeciwko HCV
MA24422A1 (fr) Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotrachaite infectieuse aviaire.
WO1993000365A3 (en) Hepatitis c virus (hcv) polypeptides
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
WO2001098333A3 (en) Modification of hepatitis b core antigen
WO2006096459A3 (en) Infectious, chimeric hepatitis c virus, methods of producing the same and methods of use thereof
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
DK0725824T3 (da) Immunodominante humane T-celleepitoper af hepatitis C virus
AU6217798A (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
AU3448797A (en) Avian recombinant live vaccine using, as vector, the avian infectious laryngotracheitis virus
EA200300129A1 (ru) Очистка антигенов вируса гепатита b (hbv) для применения в вакцинах
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
EP1399481A4 (en) RECOMBINANT ANTIBODIES TO INFECTIOUS BURSAL DISEASE VIRUS (IBDV)
AU2001246331A1 (en) Hepatitis b virus (hbv) antigenic polypeptide-heat shock protein complex and use thereof
MXPA03009763A (es) Vacuna contra el virus de la enfermedad de la fiebre aftosa.
WO2002026785A3 (de) Cd4+ t-lymphozyten spezifische hepatitis c virus-epitope
WO2004058807A3 (en) Mhc class i restricted t-cell stimulating peptides from hepatitis b virus
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
AU2000252449A1 (en) Recombinant vaccines against infectious bursal disease virus
DE602004028512D1 (de) Rekombinante vakzine gegen infektion mit dem japanischen enzephalitis-virus äjevü und verfahren davon
HU0102823D0 (en) A broad spectrum infectious bursal disease virus vaccine
PT1194450E (pt) Vacina inactivada contra a calicivirose felina
CA2072982A1 (en) Hepatitis a vaccines
AU2002314610A1 (en) Attenuated very virulent infectious bursal disease virus
DK1448223T3 (da) Thymosin-forögelse af genetisk immunisering